Premium
Management of chronic lymphocytic leukemia ( CLL ) in the era of B ‐cell receptor signal transduction inhibitors
Author(s) -
Mato Anthony,
Jauhari Shekeab,
Schuster Stephen J.
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24021
Subject(s) - chronic lymphocytic leukemia , breakpoint cluster region , medicine , signal transduction , cancer research , leukemia , lymphoma , ibrutinib , immunology , b cell receptor , receptor , b cell , biology , antibody , biochemistry
The treatment of patients with chronic lymphocytic leukemia (CLL), an indolent B‐cell lymphoma is in the midst of a transformation. There are a large number of promising new therapeutic agents and cellular therapies being studied which exhibit remarkable activity, favorable toxicity profiles, convenient administration schedules, and treatment options are rapidly expanding. The recent advances in the management of CLL exemplify the value of translational medicine. This review highlights key aspects of B‐cell receptor (BCR) signaling in relation to novel inhibitors of the BCR signaling pathway, currently at various stages of preclinical and clinical development. Am. J. Hematol. 90:657–664, 2015. © 2015 Wiley Periodicals, Inc.